3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Not yet recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Stomach Neoplasms
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Lung Neoplasms
2
Adenocarcinoma Of Esophagus
2
Urothelial Bladder Carcinoma
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Solid Tumor
1
Sarcoma
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Liver Neoplasms
1
Liposarcoma
1
Glioblastoma
1
Esophageal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Advanced Non-Small Cell Lung Cancer
1
Interventions
Gemcitabine
18
pembrolizumab
16
Cisplatin
16
Nivolumab
15
atezolizumab
11
durvalumab
9
Specimen Handling
9
Magnetic Resonance Spectroscopy
9
Cystectomy
8
Carboplatin
7
Ipilimumab
6
Fluorouracil
6
avelumab
5
Mitomycin
5
sacituzumab govitecan
4
erdafitinib
4
enfortumab vedotin
4
Surgical Procedures, Operative
4
Immunoglobulin G
4
Disulfides
4
Biopsy
4
tremelimumab
3
cabozantinib
3
Transurethral Resection of Bladder
3
Surveys and Questionnaires
3
Radiation
3
Platinum
3
Paclitaxel
3
Leucovorin
3
Docetaxel
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Urinary Bladder Neoplasms
×
zimberelimab
×
Clear all
NCT05891171
2026-06-05
ARC-25
Arcus Biosciences, Inc.
Phase 1
Active not recruiting
40 enrolled